Document Type
Article
Publication Date
Spring 5-1-2014
Abstract
To describe factors associated with multidrug-resistant (MDR), including extensively-drug-resistant (XDR), tuberculosis (TB) in the United States, we abstracted inpatient, laboratory, and public health clinic records of a sample of MDR TB patients reported to the Centers for Disease Control and Prevention from California, New York City, and Texas during 2005–2007. At initial diagnosis, MDR TB was detected in 94% of 130 MDR TB patients and XDR TB in 80% of 5 XDR TB patients. Mutually exclusive resistance was 4% XDR, 17% pre-XDR, 24% total first-line resistance, 43% isoniazid/rifampin/rifabutin-plus-other resistance, and 13% isoniazid/rifampin/rifabutin-only resistance. Nearly three-quarters of patients were hospitalized, 78% completed treatment, and 9% died during treatment. Direct costs, mostly covered by the public sector, averaged $134,000 per MDR TB and $430,000 per XDR TB patient; in comparison, estimated cost per non-MDR TB patient is $17,000. Drug resistance was extensive, care was complex, treatment completion rates were high, and treatment was expensive.
Persistant Identifier
http://hdl.handle.net/10950/4544
Publisher
CDC
Permanent Email Address
archivist@uttyler.edu
Recommended Citation
Marks, Suzanne M.; Flood, Jennifer; Seaworth, Barbara; Hirsch-Moverman, Yael; Armstrong, Lori; Mase, Sundari; Salcedo, Katya; Oh, Peter; Graviss, Edward A.; Colson, Paul W.; Armitige, Lisa; Revuelta, Manuel; Sheeran, Kathryn; and TB Epidemiologic Studies Consortium, "Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007" (2014). School of Medicine Faculty Publications and Presentations. Paper 6.
Description
This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.